ReviewChildren (Basel, Switzerland)2020
Advances in Pediatric Acute Promyelocytic Leukemia.
Review in Children (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study.Journal of cancer research and clinical oncology · 2021Trial
- Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil.Cancer reports (Hoboken, N.J.) · 2026Article
- Therapeutic outcomes of acute promyelocytic leukemia in children.Leukemia research reports · 2026Article
- Pro-Apoptotic and Cytotoxic Effects of Melittin on HL-60 Acute Promyelocytic Leukemia Cells: Implications for Retinoid-Independent Therapy.Molecules (Basel, Switzerland) · 2025Article
- Regulatory Role of Zinc in Acute Promyelocytic Leukemia: Cellular and Molecular Aspects with Therapeutic Implications.International journal of molecular sciences · 2025Review
- Clinical profile and treatment outcomes in paediatric and adult acute promyelocytic leukemia: experience from a tertiary care centre in Northern India.Annals of hematology · 2025Article
- Azacitidine as maintenance therapy in pediatricFrontiers in immunology · 2025Article
- Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.British journal of haematology · 2025Article
- Exploration of neuroprotective strategies in patients with acute promyelocytic leukemia complicated by cerebral hemorrhage.Frontiers in medicine · 2025Review
- Acute promyelocytic leukemia withOncology letters · 2024Article
- A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital.Frontiers in oncology · 2023Article
- Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population-based study.International journal of cancer · 2022Article
- Straight to the Point-The Novel Strategies to Cure Pediatric AML.International journal of molecular sciences · 2022Review
- Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells.Cancers · 2021Review
- Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions.Children (Basel, Switzerland) · 2021Article
- Review
- Article
- Narrative review of targetable features of pediatric acute myeloid leukemia from molecular and metabolic perspectives.Pediatric medicine (Hong Kong, China) · 2021Article
- Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is a rare disease accounting for only 5%-10% of pediatric acute myeloid leukemia (AML) and fewer than 1000 cases occur annually in the United States across all age groups. Characterized by t (15; 17), with a resultant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.